pharmaceutical drug development services of pharmaceutical products intended for the treatment of infectious diseases, namely, bacterial, fungal, parasitic and viral infections; pharmaceutical drug development services of pharmaceutical products intended for the treatment of neoplastic disorders, namely, hematologic cancer disorders and solid tumors; pharmaceutical drug development services of pharmaceutical products intended for the treatment of autoimmune disorders, namely, diabetes, arthritis, psoriasis, bone marrow and organ transplantation and immunosuppression; pharmaceutical drug development services of pharmaceutical products intended for the treatment of metabolic disorders, namely, obesity and atherosclerosis; pharmaceutical drug development services of pharmaceutical products intended for the treatment of cardiovascular disorders, namely, hypertension, congestive heart failure, myocardial infarction, angina and vascular diseases; pharmaceutical drug development services of pharmaceutical products intended for the treatment of renal disorders, namely, acute and chronic renal failure and urinary disorders affecting renal conservation of water; pharmaceutical drug development services of pharmaceutical products intended for the treatment of central nervous system disorders, namely, analgesia, anesthesia, hypnotics, sedatives, anxiety, psychosis, depression, mania, epilepsies, migraine, neurodegeneration, and drug addiction; pharmaceutical drug development services of pharmaceutical products intended for the treatment of inflammatory disorders, namely, asthma, gout, inflammatory bowel disease, and rheumatoid arthritis; pharmaceutical drug development services of pharmaceutical products intended for the treatment of gastrointestinal disorders, namely, ulcers, emesis, diarrhea, and irritable bowel syndrome; pharmaceutical drug development services of pharmaceutical products intended for the treatment of hormonal disorders affecting the thyroid, estrogens, progestins, androgens, glucocorticoids, insulin and glucose regulation; pharmaceutical drug development services of pharmaceutical products intended for the treatment of calcification and bone turnover; and pharmaceutical drug development services of pharmaceutical products intended for the treatment of dermatological and opthalmological disorders

First Use Date in General

31^st Mar 2006

First Use Date in Commerce

31^st Mar 2006

Mark Details

Serial Number

No 78596173

Mark Type

No Service Mark

Attorney Docket Number

No 1424849.4000

44D Filed

44D Current

44E filed

44E Current

66A Filed

66A Current

Current Basis

No Basis

Legal History

Status Date	Action Taken
03^rd Oct 2019	REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
03^rd Oct 2019	NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
03^rd Oct 2019	REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
03^rd Oct 2019	CASE ASSIGNED TO POST REGISTRATION PARALEGAL
23^rd Aug 2019	TEAS SECTION 8 & 9 RECEIVED
25^th Aug 2018	COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
22^nd Jan 2016	TEAS CHANGE OF CORRESPONDENCE RECEIVED
25^th Sep 2015	NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
25^th Sep 2015	REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
25^th Sep 2015	CASE ASSIGNED TO POST REGISTRATION PARALEGAL

INDUS PHARMACEUTICALS

Classification Information

Class [042]Computer & Software Services & Scientific Services